Standardization and performance evaluation of “modified” and “ultrasensitive” versions of the Abbott RealTi me HIV-1 assay, adapted to quantify minimal residual viremia

Abstract

Background Numerous studies investigating clinical significance of HIV-1 minimal residual viremia (MRV) suggest potential utility of assays more sensitive than those routinely used to monitor viral suppression. However currently available methods, based on different technologies, show great variation in detection limit and input plasma volume, and generally suffer from lack of standardization. Objectives In order to establish new tools suitable for routine quantification of minimal residual viremia in patients under virological suppression, some modifications were introduced into standard procedure of the Abbott RealTi me HIV-1 assay leading to a “modified” and an “ultrasensitive” protocols. Study design The following modifications were introduced: calibration curve extended towards low HIV-1 RNA concentration; 4 fold increased sample volume by concentrating starting material; reduced volume of internal control; adoption of “open-mode” software for quantification. Analytical performances were evaluated using the HIV-1 RNA Working Reagent 1 for NAT assays (NIBSC). Both tests were applied to clinical samples from virologically suppressed patients. Results The “modified” and the “ultrasensitive” configurations of the assay reached a limit of detection of 18.8 (95% CI: 11.1–51.0 cp/mL) and 4.8 cp/mL (95% CI: 2.6–9.1 cp/mL), respectively, with high precision and accuracy. In clinical samples from virologically suppressed patients, “modified” and “ultrasensitive” protocols allowed to detect and quantify HIV RNA in 12.7% and 46.6%, respectively, of samples resulted “not-detectable”, and in 70.0% and 69.5%, respectively, of samples “detected <40 cp/mL” in the standard assay. Conclusions The “modified” and “ultrasensitive” assays are precise and accurate, and easily adoptable in routine diagnostic laboratories for measuring MRV.